Integrin α10-Selected MSC Composition for Chronic Skin Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic skin wounds and burns, such as those caused by diabetes, vascular insufficiency, pressure sores, and burns, face challenges including heterogeneous cell compositions, slow proliferation, difficulty in isolation, and limited healing capabilities of existing stem cell therapies, leading to prolonged healing times and scarring.
Innovation Solution
The use of integrin alpha 10-selected Mesenchymal Stem Cells (MSCs), which are enriched and selected based on integrin alpha 10 expression, provides a homogeneous cell composition with superior immunomodulatory and anti-inflammatory properties, promoting robust wound healing and reducing scarring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If heterogenous MSC populations are used for wound treatment, then cell availability is improved, but healing efficacy and immunomodulatory capability are reduced
Solution Approach 1:
The patent extracts and isolates the specific integrin alpha 10-positive MSC subset from the heterogeneous MSC population. This selective extraction of the therapeutically active cell subset resolves the contradiction by providing a purified cell population that maintains availability while maximizing healing efficacy and immunomodulatory capability.
Solution Approach 2:
The patent applies local quality by creating a heterogeneous cell composition with specific proportions of different cell types (integrin alpha 10-positive MSCs, integrin alpha 10-negative MSCs, and keratinocytes). This localized optimization of cell composition resolves the contradiction by combining the availability of heterogeneous populations with the enhanced efficacy of selected cell subsets.
2Reliability
If traditional wound management policies are applied, then mortality rate decreases, but functional and aesthetic outcomes for extensive burns remain poor
Solution Approach 1:
The patent changes the cellular parameter by introducing integrin alpha 10-selected MSCs with specific immunomodulatory properties. This parameter change resolves the contradiction by maintaining the life-saving benefits of traditional management while adding regenerative capabilities that improve functional and aesthetic outcomes through controlled cell differentiation and tissue regeneration.
Data Source
AI summary
The present invention relates to therapeutics and methods for treating skin defects using compositions comprising integrin al0-selected Mesenchymal Stem Cells (MSCs) Disclosed herein are integrin α10-selected MSC populations and culture conditions that enhance cell viability, paracrine activity, and regenerative function when administered to damaged skin tissue. The compositions promote wound healing, modulate inflammatory responses, and support re-epithelialization. Further disclosed herein are dosing parameters and administration routes suitable for improving healing outcomes in acute and chronic skin defects.